🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD

Recruitingn/aAges 18 Years - anyAllUniversity of Patras
NCT07491523 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Patients with ssc-ild receiving double immunosuppression with or without anti fibrotic tratment

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria:ild-ssc with double immunosuppression \- Exclusion Criteria: * ssc without ild
💊

What it tests

  • Antifibrotic drugs (nidanib or pirfenidone)
  • MMF Immunosuppression
📍

Where

1 site
University of patras
Pátrai, Greece
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy